AbbVie bases Alzheimer’s effort in Cambridge

Comments Print Craig F. Walker/Globe Staff AbbVie Inc. vice president Eric Karran and chief scientific officer Michael Severino at the company’s new research facility in Cambridge. CAMBRIDGE — AbbVie Inc. will direct an effort to cure Alzheimer’s disease from its new research facility in Cambridge. The drug maker, based in North Chicago, Ill., on Wednesday formally opened a 43,000-square-foot Foundational Neuroscience Center on two floors of a former Vertex Pharmaceuticals Inc. building on Sidney Street. AbbVie vice president Eric Karran, a biopharma veteran hired from the United Kingdom to lead the new center, said its mission is ambitious: to take on Alzheimer’s, the neurodegenerative disease estimated to affect more than 40 million people worldwide. “There’s a group of people who don’t know about the Foundational Neuroscience Center, but they will,”…

Link to Full Article: AbbVie bases Alzheimer’s effort in Cambridge

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!